Myungmoon Pharmaceutical Rises 12.52% Amid COVID-19 (Nafamostat) Theme Surge

On the 6th, the COVID-19 (Nafamostat) theme showed strength by rising 3.19% compared to the previous day, while Myungmoon Pharmaceutical, which is attracting attention as a related stock, surged 12.52% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focused on prescription drugs.

[Graph] Major stock price changes in the COVID-19 (Nafamostat) theme

According to preliminary data compiled at 14:36, foreigners are net buying 10,000 shares of Myungmoon Pharmaceutical.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 5.66 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (Nafamostat). This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, Chong Kun Dang Holdings ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.